Italy· 044928024
EPCLUSA*28 cpr rivestite 200 mg + 50 mg flacone
A sofosbuvir and velpatasvir product containing sofosbuvir/velpatasvir, registered in Italy by GILEAD SCIENCES IRELAND UC, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Sofosbuvir and velpatasvir is registered in 16 of 19 countries.
Countries holding a registration under ATC J05AP55 (sofosbuvir and velpatasvir), each read from that country’s own register.
- This record: Italy
- 11 of them publish a price we can compare per daily dose
Sofosbuvir and velpatasvir · ATC J05AP55
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
- Active substance
- Sofosbuvir/Velpatasvir
- Manufacturer
- GILEAD SCIENCES IRELAND UC
- Country
- Italy (IT)
- ATC code
- J05AP55
- ATC class
- Sofosbuvir and velpatasvir
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic044928024EPCLUSA*28 cpr rivestite 200 mg + 50 mg flaconeEUR 24824.77
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
80 interactions on record for sofosbuvir and velpatasvir.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sofosbuvir and velpatasvir · interactions on record
80 records
- 14 severe
- 61 moderate
- 5 minor
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J05AP55
Sofosbuvir and velpatasvir, as other registers publish it.
- FinlandEpclusaParanova Oy
- United StatesEpclusaGilead Sciences, Inc.
- FinlandEpclusaGilead Sciences Ireland UC
- FinlandEpclusaGilead Sciences Ireland UC
- DenmarkEpclusaGilead Sciences Ireland UC
- DenmarkEpclusaGilead Sciences Ireland UC
- United StatesEpclusaGilead Sciences, Inc.
- FinlandEpclusaGilead Sciences Ireland UC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bcee6a05-315c-4fb0-bbf8-6e9e18ba9e34 GET /v1/drugs/bcee6a05-315c-4fb0-bbf8-6e9e18ba9e34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 24824.77,
"source": "aifa",
"currency": "EUR",
"strength": "SOFOSBUVIR+VELPATASVIR 200+50MG 28 UNITA' USO ORALE",
"substance": "Sofosbuvir/Velpatasvir",
"equivalence_group": "LGW",
"transparency_flag": null
}See everything about sofosbuvir and velpatasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.